Summary:
Click image to enlarge
This 24 month treatment, multicenter, double-blind, placebo-controlled, parallet group, Phase 3 study in participants with Early Alzheimer's Disease (EAD) including mild cognitive impairment (MCI) due to AD/Prodromal AD and the early stages of mild AD will be conducted to evaluate the efficacy and safety of E2609.
Qualified Participants Must:
• Be between 50 and 85 years of age
•
Be experiencing noticable changes in memory or thinking
•
Have a regular informant/study partner available
Qualified Participants May Receive:
Compnsations is available for time and travel for both participant and the study partner.